Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

ABBV-295

A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

AbbVie · Phase 1 · Active, not recruiting · Enrollment 80

NCT07291232

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
ABBV-295 or Placebo-Group 1n/rn/rn/rn/r
ABBV-295 or Placebo-Group 2n/rn/rn/rn/r
ABBV-295 or Placebo-Group 3n/rn/rn/rn/r
ABBV-295 or Placebo-Group 3 Extensionn/rn/rn/rn/r
ABBV-295 or Placebo-Group 4n/rn/rn/rn/r
ABBV-295 or Placebo-Group 4 Extensionn/rn/rn/rn/r
ABBV-295 or Placebo-Group 5n/rn/rn/rn/r
ABBV-295 or Placebo-Group 6n/rn/rn/rn/r

Not shown

  • ABBV-295 or Placebo-Group 1: endpoint not reported
  • ABBV-295 or Placebo-Group 2: endpoint not reported
  • ABBV-295 or Placebo-Group 3: endpoint not reported
  • ABBV-295 or Placebo-Group 3 Extension: endpoint not reported
  • ABBV-295 or Placebo-Group 4: endpoint not reported
  • ABBV-295 or Placebo-Group 4 Extension: endpoint not reported
  • ABBV-295 or Placebo-Group 5: endpoint not reported
  • ABBV-295 or Placebo-Group 6: endpoint not reported